InzucchiSE, BergenstalRM, BuseJB, DiamantM, FerranniniE, NauckM, PetersAL, TsapasA, WenderR, MatthewsDR: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015; 38:140–149.
2.
GarberAJ, AbrahamsonMJ, BarzilayJI, BlondeL, BloomgardenZT, BushMA, Dagogo-JackS, DeFronzoRA, EinhornD, FonsecaVA, GarberJR, GarveyWT, GrunbergerG, HandelsmanY, HenryRR, HirschIB, JellingerPS, McGillJB, MechanickJI, RosenblitPD, UmpierrezGE: Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2016 executive summary. Endocr Pract, 2016; 22:84–113.
3.
ZhouG, MyersR, LiY, ChenY, ShenX, Fenyk-MelodyJ, WuM, VentreJ, DoebberT, FujiiN, MusiN, HirshmanMF, GoodyearLJ, MollerDE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001; 108:1167–1174.
NathanDM, BuseJB, DavidsonMB, FerranniniE, HolmanRR, SherwinR, ZinmanB; American Diabetes Association; European Association for the Study of Diabetes: Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009; 52:17–30.
6.
RojasLB, GomesMB: Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr, 2013; 5:6.
7.
ProvincialiN, LazzeroniM, CazzanigaM, GorleroF, DunnBK, DeCensiA: Metformin: risk-benefit profile with a focus on cancer. Expert Opin Drug Saf, 2015; 14:1573–1585.
8.
FanH, SunX, ZhangH, LiuJ, ZhangP, XuY, PanQ, WangG: Effect of metformin on fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes. Diabetes Technol Ther, 2016; 18:120–126.
9.
ChengX, ZhuB, JiangF, FanH: Serum FGF-21 levels in type 2 diabetic patients. Endocr Res, 2011; 36:142–148.
10.
WooYC, XuA, WangY, LamKS: Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 2013; 78:489–496.
11.
KharitonenkovA, AdamsAC: Inventing new medicines: the FGF21 story. Mol Metab, 2013; 3:221–229.
